Foghorn Therapeutics (FHTX) EBITDA Margin (2020 - 2026)
Foghorn Therapeutics (FHTX) recorded quarterly EBITDA Margin of 613.16% in Q1 2026, down 161.72% quarter-over-quarter from 234.28% in Q4 2025, and down 29470.0% on a YoY basis from N/an in Q1 2025.
Foghorn Therapeutics (FHTX) EBITDA Margin (2020 - 2026) Analysis & Trends
Foghorn Therapeutics' EBITDA Margin history runs 7 years deep, the most recent figure standing at 613.16% for Q1 2026.
- In Q1 2026, EBITDA Margin fell 29470.0% year-over-year to 613.16%; the TTM figure through Mar 2026 stood at 267.4% (up 7266.0% YoY), while the FY2025 annual figure was 240.69%, up 13830.0% from the prior year.
- EBITDA Margin was 613.16% for Q1 2026 at Foghorn Therapeutics, down from 234.28% in the prior quarter.
- In the past five years, EBITDA Margin ranged from a high of 77.35% in Q3 2023 to a low of 716.79% in Q1 2022.
- Historically, EBITDA Margin has averaged 432.41% across 5 years, with a median of 413.69% in 2022.
- The sharpest annual moves came in 2022 and 2026: EBITDA Margin jumped 6320339 bps in 2022, then tumbled 29470 bps in 2026.
- A 5-year view of EBITDA Margin shows it stood at 669.41% in 2022, then soared by 40 bps to 399.36% in 2023, then tumbled by 73 bps to 690.76% in 2024, then soared by 66 bps to 234.28% in 2025, then sank by 162 bps to 613.16% in 2026.
- The last three EBITDA Margin figures came in at 613.16% (Q1 2026), 234.28% (Q4 2025), and 193.56% (Q3 2025), per Business Quant data.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | EBITDA Margin (Qtr) |
|---|---|---|---|---|---|
| 1 | Alterity Therapeutics | 925,601.88 Bn | 925,601.85 Bn | - | - |
| 2 | Belite Bio | 58,560.00 Bn | 58,560.00 Bn | - | - |
| 3 | Quantum Biopharma | 17,284.41 Bn | 17,284.40 Bn | - | - |
| 4 | Legend Biotech | 2,809.00 Bn | 2,808.71 Bn | 242.10 Mn | -6.43% |
| 5 | Evaxion A | 1,334.43 Bn | 1,334.42 Bn | - | - |
| 6 | Akari Therapeutics | 1,312.27 Bn | 1,312.26 Bn | - | - |
| 7 | Psyence Biomedical | 212.16 Bn | 212.16 Bn | - | - |
| 8 | Vertex Pharmaceuticals | 114.83 Bn | 107.58 Bn | 2.59 Bn | 38.10% |
| 9 | Abivax | 91.96 Bn | 91.96 Bn | - | - |
| 10 | Foghorn Therapeutics | 282.33 Mn | 193.42 Mn | - | -613.16% |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | -613.16% |
| Dec 31, 2025 | -234.28% |
| Sep 30, 2025 | -193.56% |
| Jun 30, 2025 | -238.11% |
| Mar 31, 2025 | -318.46% |
| Dec 31, 2024 | -690.76% |
| Sep 30, 2024 | -235.96% |
| Jun 30, 2024 | -331.30% |
| Mar 31, 2024 | -488.85% |
| Dec 31, 2023 | -399.36% |
| Sep 30, 2023 | -77.35% |
| Jun 30, 2023 | -523.95% |
| Mar 31, 2023 | -553.25% |
| Dec 31, 2022 | -669.41% |
| Sep 30, 2022 | -413.69% |
| Jun 30, 2022 | -652.74% |
| Mar 31, 2022 | -716.79% |
| Dec 31, 2021 | -4,083.73% |
| Sep 30, 2021 | -63,617.07% |
| Jun 30, 2021 | -8,289.25% |